{"brief_title": "Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)", "brief_summary": "The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.", "condition": ["Chronic Hepatitis C", "Cirrhosis"], "intervention_type": ["Biological"], "intervention_name": ["peginterferon alfa-2b (SCH 54031)"], "description": ["0.5 \u00b5g/kg subcutaneously once weekly for 60 months"], "arm_group_label": ["PegIntron"], "other_name": ["PegIntron"], "criteria": "Inclusion Criteria: - Age at entry 18-65 years; - Non-responders to previous treatment (minimum of 3 months) with an alpha interferon plus ribavirin; - Liver biopsy demonstrating cirrhosis Exclusion Criteria: - Any other cause for liver disease other than chronic hepatitis C; - History or presence of complications of cirrhosis; - Alcohol or illicit drug abuse or treatment with methadone within the past 2 years; - Diseases or conditions that could interfere with participation in the study", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "Hepatitis C; Cirrhosis", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis C", "Hepatitis, Chronic", "Hepatitis C, Chronic", "Fibrosis", "Liver Cirrhosis", "Peginterferon alfa-2b", "Interferon-alpha"], "id": "NCT00048724"}